Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference at 12:30 p.m. EDT/6:30 p.m. CEST on Sunday, August 28, 2011, to review data presented at the European Society of Cardiology meeting in Paris. Company executives will provide an overview of data presented at the meeting and address inquiries from investors and analysts.

The meeting will take place in the New Orleans Room at the Hilton Paris Charles De Gaulle Airport. Investors and the general public are invited to listen to a live webcast of the call at: http://investor.bms.com or by dialing 719-325-4878, confirmation code: 1476086. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 3:30pm EDT on August 28 through midnight EDT on September 12. The replay can be accessed at http://investor.bms.com or by dialing 402-280-9013, confirmation code: 1476086.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  Europe  North America  France  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.